SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Orgovyx

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval December 18, 2020).
Why 3/10
Orgovyx is already approved and commercially marketed with no pending FDA decision or pivotal readout. For Pfizer, it is a co-commercialized product shared with Sumitomo Pharma and represents a very small fraction of Pfizer's $63B+ annual revenue. No hard binary catalyst exists in the next 12 months, capping the score at 3-5 per the rubric for approved drugs with no pending regulatory decision.
Actionable Insight NEUTRAL

Orgovyx is an already-approved, commercially mature drug with no upcoming FDA decision or pivotal readout. For Pfizer investors, the drug's sales trajectory matters only at the margins of a $63B+ revenue base. The next notable event is whether Orgovyx crosses the $1 billion annual sales threshold, which would trigger a $325 million milestone payment from Pfizer to Sumitomo (already factored into Sumitomo's guidance). Watch Sumitomo Pharma's quarterly reports for Orgovyx sales trends and any label expansion efforts.

Price Chart

Loading chart...

Executive Summary

Orgovyx (relugolix) is an oral GnRH receptor antagonist approved by the FDA in December 2020 for advanced prostate cancer. It was the first oral hormone therapy for this indication, offering a convenient once-daily pill alternative to injectable treatments like Lupron. Originally developed by Myovant Sciences (acquired by Sumitomo Pharma in 2023), Orgovyx is co-commercialized in the US and Canada by Sumitomo Pharma America and Pfizer under a 2020 profit-sharing collaboration. The drug has posted strong sales growth (approaching $1 billion annually) but is a very small component of Pfizer's $63B+ revenue base. No new regulatory catalysts are pending for this already-approved, marketed drug.

How It Works

Orgovyx is a once-daily pill that blocks a hormone signal in the brain (GnRH), which in turn stops the testicles from producing testosterone. Since prostate cancer cells rely on testosterone to grow, lowering testosterone levels slows the cancer's progression. It is the first oral version of this type of therapy, previously only available as injections or implants.

Trial Status

Orgovyx was approved by the FDA on December 18, 2020 based on the Phase 3 HERO trial, which showed it suppressed testosterone faster and with better cardiovascular safety than the injectable standard-of-care leuprolide (Lupron). Post-approval, the OPTYX real-world study (NCT05467176) completed enrollment and reported that over 52% of patients preferred oral Orgovyx over injectable ADT. The drug is commercially marketed in the US and has regulatory approvals in Europe and other regions.

The Two-Sided Case

▲ Bull Case4
First and only oral GnRH antagonist for advanced prostate cancer, offering a convenience advantage over injectable Lupron and other injectable ADT options
Strong commercial momentum: Orgovyx sales reached $777 million in North America in the first 9 months of Sumitomo's FY2025 (through Dec 2025), with management calling a $1 billion annual sales milestone 'almost certain to be achieved'
Favorable clinical profile: Phase 3 HERO trial showed faster testosterone suppression and lower risk of major adverse cardiovascular events compared to leuprolide
Patent protection until at least September 2037 provides a long runway before generic competition
▼ Bear Case4
For Pfizer specifically, Orgovyx is a co-commercialized product with profit-sharing; it is not a top-10 revenue driver and is not separately reported in Pfizer's product revenue tables
CE exclusivity for Orgovyx expired in December 2025, exposing it to potential generic competition sooner than the last patent expiry date
Injectable GnRH agonists like Lupron remain entrenched standard-of-care with decades of clinical use and established reimbursement
The broader ADT market includes multiple competitors including newer injectable GnRH antagonists like Firmagon (degarelix), and the convenience advantage of an oral pill may not fully offset higher out-of-pocket costs for some patients

Upcoming Catalysts

  • Potential $1 billion annual sales milestone triggering $325M milestone payment (already expected by Sumitomo management for FY2026)
  • Possible label expansion or new indication studies for relugolix (e.g., combination therapy for women's health as Myfembree)
  • Patent challenges: one Paragraph IV challenge filed; last Orange Book patent expires September 29, 2037

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 pfizer.com3 pfizer.com4 sumitomo-pharma.com5 filingreader.com6 finance.biggo.com7 drugpatentwatch.com8 targetedonc.com9 en.wikipedia.org10 sumitomo-pharma.com